Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 17/20 | 0.64 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13821413 | 0.99 | BTK (0.63) | BTKCLK2KDM4ERAB9AHPGD | |
| SCHEMBL13765472 | 0.99 | BTK (0.63) | BTKCLK2KDM4ERAB9AHPGD | |
| SCHEMBL13765458 | 0.98 | BTK (0.64) | BTKCLK2KDM4ERAB9AHPGD | |
| SCHEMBL13765464 | 0.98 | BTK (0.66) | BTKCLK2KDM4ERAB9ATYK2 | |
| SCHEMBL13765480 | 0.94 | BTK (0.60) | BTKCLK2KDM4ERAB9A | |
| SCHEMBL13765479 | 0.94 | BTK (0.62) | BTKCLK2KDM4ERAB9A | |
| SCHEMBL13765490 | 0.93 | BTK (0.63) | BTKCLK2KDM4ERAB9ATYK2 | |
| SCHEMBL13765482 | 0.93 | BTK (0.60) | BTKCLK2KDM4ERAB9A | |
| SCHEMBL13765470 | 0.93 | BTK (0.61) | BTKCLK2KDM4ERAB9ATYK2 | |
| SCHEMBL13765496 | 0.93 | BTK (0.61) | BTKCLK2KDM4ERAB9ATYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| WO-2009077334-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | BTK 1/4885CLK2 351/4885KDM4E 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.